Brief: AIM Immunotech Announces FDA Clearance Of IND Application To Evaluate Ampligen In Phase 2 Clinical Study For Treatment Of Post-Covid Conditions
12/10/2022 22:30
Oct 12 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH ANNOUNCES FDA CLEARANCE OF IND APPLICATION
TO
EVALUATE AMPLIGEN® IN PHASE 2 CLINICAL STUDY FOR THE TREATMENT
OF POST-COVID CONDITIONS
* AIM IMMUNOTECH INC - CO EXPECTS TO COMMENCE PATIENT
ENROLLMENT
AND DOSING IN AMP-518 STUDY IN Q1 2023
Source text for Eikon: ID:nGNX37jz5f
Further company coverage: AIM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential